Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.
Perianal fistulizing Crohn’s disease remains difficult to treat, and no validated biomarkers exist to guide pharmacological treatment selection despite advances in molecular profiling.